Bio-Techne Corp is a biotechnology company that specializes in developing and producing high-quality biotechnology tools and reagents for the life sciences market. The company offers a wide range of products, including proteins, antibodies, assays, and diagnostic tools, which are used by researchers and clinical laboratories for various applications, such as drug development, diagnostics, and disease research. With a focus on innovation, Bio-Techne aims to provide cutting-edge solutions that enhance research capabilities and improve patient outcomes in healthcare. Read More
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer Price Index (CPI) report, investors are increasingly betting on a rate reduction next month, a sentiment amplified by U.S. Treasury Secretary Scott Bessent's call for a significant cut. This has fueled a 'risk-on' environment across Wall Street. Lower interest rates are typically beneficial for growth-oriented sectors like healthcare, as they reduce the cost of borrowing for research and innovation and increase the present value of future earnings.
A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare.
Life sciences company Bio-Techne (NASDAQ:TECH) announced better-than-expected revenue in Q2 CY2025, with sales up 3.5% year on year to $317 million. Its non-GAAP profit of $0.53 per share was 6.1% above analysts’ consensus estimates.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 13.8%. This drop is a far cry from the S&P 500’s 5.3% ascent.
Shares of life sciences company Bio-Techne (NASDAQ:TECH)
fell 6.5% in the afternoon session after the company reported its fourth-quarter fiscal 2025 results, which included a significant net loss driven by a large impairment charge. The company posted a net loss of $17.68 million, a sharp reversal from the $40.59 million in net income recorded a year ago. This loss resulted from an $83.1 million impairment charge linked to the divestiture of its Exosome Diagnostics business. An impairment charge is an accounting entry used when an asset's value falls below its recorded worth. Furthermore, the company's gross margin tightened and it recorded an operating loss of $23.9 million, compared to an operating profit of $45.8 million in the prior year. The Diagnostics and Spatial Biology division also experienced a 1% decrease in sales.
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session.
Curious about the market action on Wednesday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
Life sciences company Bio-Techne (NASDAQ:TECH) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 3.5% year on year to $317 million. Its non-GAAP profit of $0.53 per share was 6.1% above analysts’ consensus estimates.
The stocks featured in this article are seeing some big returns.
Over the past month, they’ve outpaced the market due to new product launches, positive news, or even a dedicated social media following.
Shares of life sciences company Bio-Techne (NASDAQ:TECH)
jumped 4.6% in the afternoon session after the investment firm Stephens initiated coverage on the stock with an "overweight" rating and a $65.00 price target.
Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights.
Spear Bio, a biotechnology company pioneering homogeneous ultrasensitive immunoassay technology, is pleased to announce a strategic distribution partnership with Bio-Techne Corporation (NASDAQ: TECH), a global leading provider of innovative reagents, instruments, and solutions for life-science research and clinical diagnostics. The partnership significantly expands global access to Spear Bio’s groundbreaking SPEAR UltraDetect™ immunoassays, focusing initially on the neurology research market. The introductory SPEAR UltraDetect offering targets biomarkers pivotal to neurodegenerative diseases, such as phosphorylated tau 231 (pTau 231), phosphorylated tau 217 (pTau 217), glial fibrillary acidic protein (GFAP), and neurofilament light (Nf‑L). This partnership follows Bio-Techne's participation in Spear Bio’s $45 million Series A funding round in 2024.
BIO-TECHNE CORP (NASDAQ:TECH) is a quality stock with strong revenue growth, high ROIC, and solid profitability, making it a candidate for long-term investors.
